#India #MASH #Ahmedabad #Saroglitazar #Zydus Therapeutics

Zydus Therapeutics Unveils Promising Phase 2b Data on Saroglitazar

In a significant breakthrough for the management of metabolic dysfunction-associated steatohepatitis (MASH), Zydus Therapeutics Inc. has announced compelling results from its Phase 2b clinical trial. The study, part of its ongoing commitment to addressing rare and serious liver diseases, demonstrated that saroglitazar effectively achieved resolution of steatohepatitis without exacerbating fibrosis in adult patients.

The trial included 189 participants with biopsy-confirmed MASH and stage F2–F3 fibrosis. According to the findings, 39.1% of patients receiving the 4 mg dose and 32.4% receiving the 2 mg dose of saroglitazar showed improvement, compared to just 13.7% of the placebo group after 52 weeks of treatment. These results signify a treatment difference of 24.9% for the higher dose and 16.5% for the lower dose, both statistically significant outcomes that propose the efficacy of saroglitazar in this demographic.

Dr. Naga Chalasani, a prominent figure in gastroenterology and hepatology, delivered the results during a late-breaking presentation at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD). The presentation highlighted that the trial is ongoing, further strengthening Zydus Therapeutics’ position in liver disease management.

“Many individuals suffering from MASH also grapple with conditions such as type 2 diabetes and obesity. Hence, it is paramount that we explore methods to simultaneously target these complications along with liver health,” remarked Dr. Chalasani. He underscored the encouraging outcomes, suggesting the potential merits of larger, more extensive studies to gauge long-term benefits.

The study further indicated that saroglitazar did not result in significant weight gain or drug-induced liver injury, which are common concerns with medications targeting liver diseases. Additionally, favorably noted improvements were observed in fibrosis assessment through non-invasive methods, cementing the investigational agent's potential therapeutic profile.

As MASH continues to grow as a major health concern due to its link to obesity and diabetes, the need for effective treatment options is urgent. The economic and health burdens posed by the disease highlight the importance of Zydus Therapeutics' efforts in pioneering solutions to address these intertwined issues. Despite the promising results, it’s noteworthy that saroglitazar remains an investigational product, and its implications for treating MASH have yet to be fully established.

The Phase 2b trial, labeled EVIDENCES X (NCT05011305), is structured as a randomized, double-blind, placebo-controlled study, gathering patients from various sites across Argentina, Turkey, and the United States. The overarching aim remains focused on determining the safety and efficacy of this novel treatment, with support from robust clinical methodologies to assess outcomes accurately.

Notably, saroglitazar is characterized as a Peroxisome Proliferator-Activated Receptor (PPAR) α/γ agonist. This distinctive mechanism positions it as a dual-target agent capable of addressing both liver inflammation and bile acid toxicity, making it a promising candidate for MASH treatment. Furthermore, it has received Orphan Drug Designation and has various FDA designations highlighting its potential in treating primary biliary cholangitis (PBC), illustrating its multifaceted clinical interest.

Zydus Therapeutics, a subsidiary of Zydus Lifesciences, emphasizes its commitment to developing innovative treatments targeted at rare liver diseases. The group prides itself on a robust pipeline of healthcare solutions, as evident from the ongoing research and trials focusing on unmet healthcare needs. Moving forward, the results from this Phase 2b trial not only help outline the path for further studies on saroglitazar but also mark a significant advance in our understanding of metabolic liver conditions.

It remains to be seen how these findings will inform future treatment protocols and patient management strategies, but the initial results are heartening for both clinicians and patients grappling with the repercussions of MASH.